Risultati della ricerca - Dipenkumar Modi
- Mostra 1 - 8 risultati su 8
-
1
CD19-directed CART therapy for T-cell/histiocyte–rich large B-cell lymphoma di Priyanka A. Pophali, Joshua Fein, Kwang Woo Ahn, Molly Allbee-Johnson, Nausheen Ahmed, Farrukh T. Awan, Shatha Farhan, Natalie S. Grover, Talal Hilal, Madiha Iqbal, Joseph E. Maakaron, Dipenkumar Modi, Elham Nasrollahi, Levanto Schachter, Craig S. Sauter, Mehdi Hamadani, Alex F. Herrera, Roni Shouval, Mazyar Shadman
Pubblicazione 2024Artigo -
2
Pembrolizumab in relapsed or refractory Hodgkin lymphoma: a post hoc analysis of KEYNOTE-204 by prior lines of therapy di John Kuruvilla, Dipenkumar Modi, Armando Santoro, Ewa Paszkiewicz‐Kozik, Robin Gasiorowski, Nathalie A. Johnson, Laura Fogliatto, Iara Gonçalves, José de Lima Oliveira, Valéria Buccheri, Guilherme Fleury Perini, Neta Goldschmidt, Iryna Kriachok, Naohiro Sekiguchi, Jianxin Lin, Rushdia Z. Yusuf, Patricia Marinello, Pier Luigi Zinzani
Pubblicazione 2025Artigo -
3
Post-Transplant Cyclophosphamide–Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors di Brian C. Shaffer, Mahasweta Gooptu, Todd E. DeFor, Martin Maiers, Javier Bolaños‐Meade, Ramzi Abboud, Adrienne Briggs, Farhad Khimani, Dipenkumar Modi, Richard Newcomb, Elizabeth J. Shpall, Caitrin Bupp, Stephen R. Spellman, Heather E. Stefanski, Bronwen E. Shaw, Jeffery J. Auletta, Steven M. Devine, Antonio Jiménez, Monzr M. Al Malki
Pubblicazione 2024Artigo -
4
Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial di Lihua E. Budde, Adam J. Olszewski, Sarit Assouline, Izidore S. Lossos, Catherine Diefenbach, Manali Kamdar, Nilanjan Ghosh, Dipenkumar Modi, Waleed Sabry, Seema Naik, Amitkumar Mehta, Shazia K. Nakhoda, Stephen D. Smith, Kathleen A. Dorritie, Ting Jia, Song Pham, Ling‐Yuh Huw, Jing Jing, Hao Wu, Wahib S. Ead, Iris To, Connie Lee Batlevi, Michael C. Wei, Julio C. Chávez
Pubblicazione 2023Artigo -
5
HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide di Ephraim J. Fuchs, Shannon R. McCurdy, Scott R. Solomon, Tao Wang, Megan M. Herr, Dipenkumar Modi, Michael R. Grunwald, Taiga Nishihori, Michelle Kuxhausen, Stephanie Fingerson, Caroline McKallor, Asad Bashey, Yvette L. Kasamon, Yung‐Tsi Bolon, Ayman Saad, Joseph P. McGuirk, Sophie Paczesny, Shahinaz M. Gadalla, Steven G. E. Marsh, Bronwen E. Shaw, Stephen R. Spellman, Stephanie J. Lee, Effie W. Petersdorf
Pubblicazione 2021Artigo -
6
HLA Haploidentical versus Matched Unrelated Donor Transplants with Post-Transplant Cyclophosphamide based prophylaxis di Mahasweta Gooptu, Rizwan Romee, Andrew St. Martin, Mukta Arora, Monzr M. Al Malki, Joseph H. Antin, Christopher Bredeson, Claudio G. Brunstein, Saurabh Chhabra, Ephraim J. Fuchs, Nilanjan Ghosh, Michael R. Grunwald, Christopher G. Kanakry, Natasha Kekre, Joseph P. McGuirk, Ian McNiece, Rohtesh S. Mehta, Marco Mielcarek, Filippo Milano, Dipenkumar Modi, Ran Reshef, Scott R. Solomon, Mark A. Schroeder, Edmund K. Waller, Yoshihiro Inamoto, Robert J. Soiffer, Mary Eapen
Pubblicazione 2021Artigo -
7
Infection after CD19 chimeric antigen receptor T cell therapy for large B cell lymphoma: Real-world analysis from CIBMTR di Kitsada Wudhikarn, Megan M. Herr, Min Chen, Michael J. Martens, John H. Baird, Lohith Gowda, Hemalatha G. Rangarajan, Muhammad Bilal Abid, Mohamed A. Kharfan‐Dabaja, Kristen M. Williams, Siddhartha Ganguly, Jo‐Anne H. Young, Akshay Sharma, Giancarlo Fatobene, Tania Jain, Christopher G. Kanakry, Dipenkumar Modi, Natalie S. Grover, Baheyeldin Salem, Marjorie Vieira Batista, Paschalis Vergidis, Dwight E. Yin, Amer Beitinjaneh, Amar H. Kelkar, Taiga Nishihori, Jennifer Holter‐Chakrabarty, Usama Gergis, Melody Smith, Zeinab El Boghdadly, Christopher E. Dandoy, Hemant S. Murthy, Anna R. Huppler, Miguel‐Angel Perales, Roy F. Chemaly, Laurel A. Thur, Marcie L. Riches, Jeffery J. Auletta
Pubblicazione 2025Artigo -
8
Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma di Reid W. Merryman, Robert Redd, Taiga Nishihori, Julio C. Chávez, Yago Nieto, Justin Darrah, Uttam K. Rao, Michael Byrne, David A. Bond, Kami J. Maddocks, Michael A. Spinner, Ranjana H. Advani, Hatcher J. Ballard, Jakub Svoboda, Anurag K. Singh, Joseph P. McGuirk, Dipenkumar Modi, Radhakrishnan Ramchandren, Jason T. Romancik, Jonathon B. Cohen, Matthew J. Frigault, Yi‐Bin Chen, Anthony V. Serritella, J. Kline, Stephen M. Ansell, Sunita Nathan, Maryam Rahimian, Robin Joyce, Mansi Shah, Kevin A. David, Steven Park, Anne Beaven, Alma Habib, Veronika Bachanová, Shazia Nakhoda, Nadia Khan, Ryan C. Lynch, Stephen D. Smith, Vincent T. Ho, Ann S. LaCasce, Philippe Armand, Alex F. Herrera
Pubblicazione 2021Artigo
Strumenti per la ricerca:
Soggetti correlati
Internal medicine
Medicine
Oncology
Immunology
Lymphoma
Refractory (planetary science)
Antigen
Astrobiology
Chemotherapy
Physics
Transplantation
Biology
CD19
Cancer
Cumulative incidence
Cyclophosphamide
Gastroenterology
Graft-versus-host disease
Human leukocyte antigen
Immunotherapy
Incidence (geometry)
Optics
Surgery
Aggressive lymphoma
Autologous stem-cell transplantation
Brentuximab vedotin
Cancer research
Cart
Chimeric antigen receptor
Cohort